Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation

Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Amino Acid Substitution / genetics
  • Anemia, Macrocytic* / complications
  • Anemia, Macrocytic* / genetics
  • Antineoplastic Agents / therapeutic use
  • Chromosome Deletion*
  • Chromosomes, Human, Pair 5 / genetics
  • Female
  • Humans
  • Janus Kinase 2 / genetics*
  • Lenalidomide
  • Middle Aged
  • Mutation, Missense / physiology
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Phenylalanine / genetics
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Treatment Outcome
  • Valine / genetics

Substances

  • Antineoplastic Agents
  • Phenylalanine
  • Thalidomide
  • JAK2 protein, human
  • Janus Kinase 2
  • Lenalidomide
  • Valine

Supplementary concepts

  • Chromosome 5q Deletion Syndrome